Enterprise Value
111.1M
Cash
340.1M
Avg Qtr Burn
N/A
Short % of Float
12.74%
Insider Ownership
4.88%
Institutional Own.
96.48%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zanidatamab (HER2) Details Cancer, Cholangiocarcinoma, Gastroesophageal adenocarcinomas | Phase 3 Data readout | |
Zanidatamab (HER2) Details Cancer, Solid tumor/s, Biliary Tract Cancer | Phase 2b Data readout | |
Zanidatamab (HER2) + chemotherapy + tislelizumab Details Cancer, Cholangiocarcinoma, Gastroesophageal adenocarcinomas | Phase 2 Update | |
Zanidatamab zovodotin (ZW49) Details HER2-expressing cancers, Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Zanidatamab (HER2) + docetaxel Details Cancer, Breast cancer | Phase 1/2 Data readout |